-- Proceeds to drive global Phase 3 trial for ASP-1929, targeting BLA submission to the U.S. FDA in 2028 -- Financing led by international life science fund TaiAx, with participation from the largest ...
Bacteria in head and neck tumor stimulate immunotherapy resistance by attracting immune cells and creating a shield.
As of December 31, 2025, the cumulative installed base of the SSi Mantra totaled 168 systems, including 12 systems deployed across nine countries outside of India. To date, 153 hospitals have ...
Merck & Co. hopes a new positive trial readout can return Keytruda to glory in head and neck cancer. After a pivotal trial failure two years ago in unresected locally advanced head and neck squamous ...
Cleveland Clinic researchers have discovered that bacteria inside cancerous tumors may be key to understanding why ...
Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Head and Neck Squamous Cell Carcinoma Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035" ...
“This collaboration underscores our belief in zanzalintinib’s potential to drive patient benefit in combination with immunotherapy or targeted therapy in HNSCC and RCC indications that have unmet ...
Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain head and neck cancers from returning. Continuous use of Keytruda—both ...
CRB-701 targets Nectin-4, delivering chemotherapy directly to cancer cells, minimizing damage to healthy tissue. The FDA's fast track designation aims to expedite CRB-701's development for HNSCC and ...
Head and neck cancer (HNC) is a prevalent malignant disease, ranking as the sixth most common cancer globally, with approximately 950,000 new cases and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback